An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

Participation Requirements

• Sex:

  ALL

• Eligible Ages:

  15 and up

Participation Criteria

Inclusion Criteria:

* Participants with a diagnosis of Crohn's disease (CD) confirmed by clinical, endoscopic and/or histological indices.
* Participants initiating risankizumab at the clinician's discretion as part of their routine clinical care.
* Participants prescribed risankizumab in accordance with the approved local label.
* Participants able to understand and communicate with the investigator and comply with the requirements of the study.
* Participants willing and able to provide authorization to use and disclose personal health information.
* Participants willing and able to participate in the collection of patient-reported data via cloud-based mobile application using a smart device (i.e., smartphone).

Exclusion Criteria:

* Females who are pregnant or breast feeding at baseline.
* Participants with any contraindication to risankizumab.
* Participants previously exposed to risankizumab.
* Participants currently participating in an interventional clinical trial.